CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.
Several other equities analysts have also recently issued reports on CRSP. Needham & Company LLC reaffirmed a "buy" rating and issued a $81.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, July 8th. Bank of America lowered their price objective on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Chardan Capital reiterated a "buy" rating and issued a $82.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, August 5th. Royal Bank Of Canada raised their target price on shares of CRISPR Therapeutics from $38.00 to $42.00 and gave the stock a "sector perform" rating in a report on Tuesday, August 5th. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 26th. Ten equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $71.50.
Read Our Latest Stock Report on CRSP
CRISPR Therapeutics Price Performance
Shares of CRSP traded up $6.16 during mid-day trading on Wednesday, hitting $76.78. The company's stock had a trading volume of 5,861,491 shares, compared to its average volume of 2,619,520. The firm has a 50-day moving average price of $58.43 and a 200 day moving average price of $48.41. The stock has a market capitalization of $6.98 billion, a price-to-earnings ratio of -14.14 and a beta of 1.84. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $78.48.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($1.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.18. The company had revenue of $0.89 million for the quarter, compared to analysts' expectations of $6.44 million. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business's revenue was up 72.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.49) EPS. As a group, equities analysts anticipate that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.
Insider Activity at CRISPR Therapeutics
In related news, Director Simeon George purchased 989,812 shares of the firm's stock in a transaction that occurred on Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the acquisition, the director owned 1,730,179 shares in the company, valued at $90,021,213.37. This trade represents a 133.69% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company's stock.
Institutional Trading of CRISPR Therapeutics
Several institutional investors have recently made changes to their positions in the stock. Ipswich Investment Management Co. Inc. boosted its holdings in shares of CRISPR Therapeutics by 0.9% during the third quarter. Ipswich Investment Management Co. Inc. now owns 25,198 shares of the company's stock worth $1,633,000 after purchasing an additional 230 shares during the period. Thrive Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth approximately $201,000. Corient Private Wealth LLC acquired a new stake in CRISPR Therapeutics in the second quarter valued at approximately $230,000. Valeo Financial Advisors LLC acquired a new stake in CRISPR Therapeutics in the second quarter valued at approximately $304,000. Finally, Reynders McVeigh Capital Management LLC lifted its stake in CRISPR Therapeutics by 9.5% in the second quarter. Reynders McVeigh Capital Management LLC now owns 111,431 shares of the company's stock valued at $5,420,000 after acquiring an additional 9,658 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.